Agilent Technologies Agreed to Acquire Proscia
The diagnostics company will purchase the digital pathology firm in a cash deal valued at $240 million.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Do you trust that corporate acquisitions of AI software companies will ultimately benefit the public?
Agilent Technologies has entered an agreement to acquire Proscia for $240 million in cash. The deal also includes up to $30 million in additional performance-based payments for the software developer.
Why it matters
The acquisition allows Agilent to expand its footprint in AI-enabled diagnostics and digital pathology. The company aims to leverage technology that converts pathology slides into digital images for advanced analysis.
Agilent is paying $240 million in cash for Proscia, with up to $30 million in performance-based bonuses available. Proscia generated over $18 million in revenue during the past 12 months.
The players
Agilent Technologies
This global leader in life sciences, diagnostics, and applied chemical markets provides instruments, software, services, and consumables for laboratory workflows.
Proscia
This software company develops digital pathology platforms that utilize artificial intelligence to help pathologists analyze and interpret tissue samples.
The details
Proscia specializes in software that transforms physical pathology slides into high-resolution digital images suitable for artificial intelligence analysis. The two companies previously collaborated under a multi-year distribution agreement established in 2022.
Timeline
The companies established a multi-year distribution agreement in 2022.
Agilent Technologies announced the acquisition on October 13, 2026.
The acquisition is expected to close in early fiscal 2027.
Market Landscape
This acquisition marks a major consolidation move, positioning Agilent to better compete in the rapidly expanding AI-enabled digital pathology platform sector. The company is betting on deep integration between its diagnostic hardware and Proscia’s image analysis software.
Healthcare providers utilizing Agilent’s diagnostic tools may soon gain access to enhanced digital pathology features through the integrated software. Patients could benefit from faster and potentially more accurate tissue sample analysis as laboratory workflows become fully digitized.
The takeaway
The integration of digital pathology software into established diagnostic chains aims to reduce manual slide interpretation time for medical professionals. Clinicians should monitor how these combined AI tools improve diagnostic turnaround speeds in clinical settings.
Further reading
For broader trends in medical innovation, visit the Healthcare section.
Live Poll
Do you trust that corporate acquisitions of AI software companies will ultimately benefit the public?
